Revolutionizing Parkinson’s Disease Treatment with Nanotechnology: A Focus on Lipid Nanoparticles
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic
neurons in the substantia nigra, leading to motor and non-motor impairments. Despite advancements in treatment, current
therapies remain largely palliative, failing to address disease progression. A major challenge in PD treatment is the restricted
delivery of therapeutics across the blood-brain barrier (BBB). Nanotechnology, particularly lipid nanoparticles (LNPs),
offers a promising drug delivery approach due to their biocompatibility, controlled release, and ability to enhance BBB
penetration. LNPs can encapsulate various therapeutic agents, including small molecules, proteins, and RNA-based
therapies, offering potential disease-modifying effects. Preclinical studies demonstrate that LNPs improve drug
bioavailability, target specificity, and therapeutic efficacy. Additionally, modifications such as PEGylation and ligand
conjugation (e.g., transferrin, angiopep-2) further enhance brain-targeted delivery. While LNPs have been successfully
applied in vaccine and gene therapy development, their potential in PD treatment remains underexplored, with limited
clinical trials. Future research should focus on optimizing LNP formulations for brain-specific delivery, leveraging genetic
therapies like RNA interference, and translating preclinical findings into clinical applications. This review highlights the
transformative potential of LNP-based nanomedicine in PD treatment, paving the way for more effective and targeted
therapeutic strategies.
neurons in the substantia nigra, leading to motor and non-motor impairments. Despite advancements in treatment, current
therapies remain largely palliative, failing to address disease progression. A major challenge in PD treatment is the restricted
delivery of therapeutics across the blood-brain barrier (BBB). Nanotechnology, particularly lipid nanoparticles (LNPs),
offers a promising drug delivery approach due to their biocompatibility, controlled release, and ability to enhance BBB
penetration. LNPs can encapsulate various therapeutic agents, including small molecules, proteins, and RNA-based
therapies, offering potential disease-modifying effects. Preclinical studies demonstrate that LNPs improve drug
bioavailability, target specificity, and therapeutic efficacy. Additionally, modifications such as PEGylation and ligand
conjugation (e.g., transferrin, angiopep-2) further enhance brain-targeted delivery. While LNPs have been successfully
applied in vaccine and gene therapy development, their potential in PD treatment remains underexplored, with limited
clinical trials. Future research should focus on optimizing LNP formulations for brain-specific delivery, leveraging genetic
therapies like RNA interference, and translating preclinical findings into clinical applications. This review highlights the
transformative potential of LNP-based nanomedicine in PD treatment, paving the way for more effective and targeted
therapeutic strategies.